ライフサイエンスコーパス: sulfadiazine

1 h those coated with chlorhexidine and silver sulfadiazine.

2 atheter coated with chlorhexidine and silver sulfadiazine.

3 nology and used as a novel device to extract sulfadiazine.

4 to use the combination of pyrimethamine and sulfadiazine.

5 rs impregnated with chlorhexidine and silver sulfadiazine.

6 as impregnated with chlorhexidine and silver sulfadiazine.

7 in vitro resistance to chlorhexidine-silver sulfadiazine.

8 ethod for separation and preconcentration of sulfadiazine.

9 ated with chlorhexidine gluconate and silver sulfadiazine.

10 .4-1196.7 mug kg(-1) in chicken samples) and sulfadiazine (109.8 mug kg(-1) in a beef sample) exceedi

11 rs impregnated with chlorhexidine and silver sulfadiazine (28 of 356 catheters [7.9 percent] vs. 87 o

12 niline (DMABN), sotalol (a beta-blocker) and sulfadiazine (a sulfonamide antibiotic) exhibited a mark

13 Catheters impregnated with silver sulfadiazine and chlorhexidine had a smaller proportion

14 iple-lumen catheters impregnated with silver sulfadiazine and chlorhexidine.

15 se of medium containing inhibitors of silver sulfadiazine and chlorhexidine.

16 ration and catheters impregnated with silver sulfadiazine and chlorhexidine; b) to decrease the numbe

17 ve, is the combination of pyrimethamine with sulfadiazine and folinic acid.

18 be compliant, but two were positive; one for sulfadiazine and the other for sulfamethoxipyridazine.

19 an until week 16, followed by pyrimethamine, sulfadiazine, and folinic acid for at least 4 weeks in c

20 s of combination therapy with pyrimethamine, sulfadiazine, and folinic acid independent of the infect

21 th a combination of chlorhexidine and silver sulfadiazine appear to be effective in reducing the inci

22 ptic combination of chlorhexidine and silver sulfadiazine are efficacious in reducing the incidence o

23 control mice were infected and treated with sulfadiazine beginning 4 days after infection for 3 week

24 The chlorhexidine-silver sulfadiazine catheter is well tolerated, reduces the inc

25 The second-generation chlorhexidine-silver sulfadiazine catheter is well tolerated.

26 e cultured from the chlorhexidine and silver sulfadiazine central venous catheters.

27 atheter coated with chlorhexidine and silver sulfadiazine (CH/SS).

28 e impact of the antiseptic effects of silver sulfadiazine-chlorhexidine-impregnated central venous ca

29 were noninferior to chlorhexidine and silver sulfadiazine coated central venous catheters with respec

30 with regular monitoring of pyrimethamine and sulfadiazine concentration in maternal blood and observa

31 AgNO3 and 5 times lower than that in silver sulfadiazine cream 1%.

32 plate, and about 6 times faster than silver sulfadiazine cream.

33 At 6 days after sulfadiazine discontinuation, cerebral tachyzoite-specif

34 n the former than the latter at 5 days after sulfadiazine discontinuation.

35 e treated with control serum at 3 days after sulfadiazine discontinuation.

36 reated with control antibody at 3 days after sulfadiazine discontinuation.

37 % (n=6) were obtained at 60mugL(-1) level of sulfadiazine for intra- and inter-day analysis respectiv

38 oup and 0.9% of the chlorhexidine and silver sulfadiazine group.

39 s were noted in the chlorhexidine and silver sulfadiazine group.

40 rs impregnated with chlorhexidine and silver sulfadiazine have recently been introduced for the preve

41 ses suggest that use of chlorhexidine-silver sulfadiazine-impregnated central venous catheters in pat

42 omized trials comparing chlorhexidine-silver sulfadiazine-impregnated central venous catheters with n

43 term use (2-10 days) of chlorhexidine-silver sulfadiazine-impregnated multilumen central venous cathe

44 s catheters; and use of chlorhexidine-silver sulfadiazine-impregnated or minocycline-rifampin-impregn

45 method was successfully applied to determine sulfadiazine in honey, milk, human urine and environment

46 theters coated with chlorhexidine and silver sulfadiazine in preventing colonization and infection wi

47 ulfonamide antibiotics (sulfamethoxazole and sulfadiazine) in the presence of untreated or preoxidize

48 uracil (n = 480) or chlorhexidine and silver sulfadiazine (n = 480).

49 ternal surfaces) or chlorhexidine and silver sulfadiazine (on only the external surface).

50 ated with chlorhexidine gluconate and silver sulfadiazine (P < .01).

51 se impregnated with chlorhexidine and silver sulfadiazine; P<0.002).

52 ine and rifampin or chlorhexidine and silver sulfadiazine reduces the rates of catheter colonization

53 [95% CI, .14-.82]), and chlorhexidine-silver sulfadiazine (RR, 0.60 [95% CI, .50-.72]) impregnations

54 amethazine (SMT), sulfamethoxazole (SMX) and sulfadiazine (SDZ) in imported Pangasius catfish product

55 ible for detection and interferences namely, sulfadiazine (SDz), sulfathiazole (STz) and sulfamerazin

56 assay reveal that 3 of these alleles encode sulfadiazine (Sdz)-sensitive enzymes.

57 severe TE and died after discontinuation of sulfadiazine, those that had received the cells did not

58 t (SCID) mice were infected and treated with sulfadiazine to establish a chronic infection.

59 SCID mice were infected and treated with sulfadiazine to establish a chronic infection.

60 ected, and one group received treatment with sulfadiazine to prevent tachyzoite proliferation during

61 mice and transferred them into infected and sulfadiazine-treated athymic nude mice, which lack T cel

62 severe TE and died after discontinuation of sulfadiazine treatment due to the reactivation of infect

63 Three days later, sulfadiazine was discontinued to initiate reactivation o

64 The retained sulfadiazine was eluted using 180muL of methanol/acetic

65 and with chlorhexidine gluconate and silver sulfadiazine were evaluated.

66 ernally coated with chlorhexidine and silver sulfadiazine when used in critically ill patients.

67 thoprim-sulfamethoxazole and/or trimethoprim-sulfadiazine with S. equi This study indicates trimethop

68 as an acceptable surrogate for trimethoprim-sulfadiazine with S. equi.

69 susceptibility test results for trimethoprim-sulfadiazine with Streptococcus equi subspecies are inte